{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:14:54Z","timestamp":1792818894667,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.jtho.2018.04.031","type":"journal-article","created":{"date-parts":[[2018,5,12]],"date-time":"2018-05-12T12:24:49Z","timestamp":1526127889000},"page":"1076-1082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":187,"title":["Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors"],"prefix":"10.1016","volume":"13","author":[{"given":"Ioannis","family":"Gkiozos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Kopitopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Kalkanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis N.","family":"Vamvakaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Judson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos N.","family":"Syrigos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2018.04.031_bib1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1742-1241.2005.00651.x","article-title":"Interferon-induced sarcoidosis","volume":"60","author":"Alazemi","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jtho.2018.04.031_bib2","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archderm.141.7.865","article-title":"Sarcoidosis associated with PEGylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature","volume":"141","author":"Hurst","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtho.2018.04.031_bib3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s535-002-8133-3","article-title":"Reactivation of sarcoidosis during interferon therapy","volume":"37","author":"Li","year":"2002","journal-title":"J\u00a0Gastroenterol"},{"issue":"2 Pt 2","key":"10.1016\/j.jtho.2018.04.031_bib4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0190-9622(99)70364-6","article-title":"Sarcoidosis in a patient with AIDS: a manifestation of immune restoration syndrome","volume":"41","author":"Mirmirani","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jtho.2018.04.031_bib5","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1378\/chest.119.3.978","article-title":"Recurrent pulmonary sarcoidosis in HIV-infected patients receiving highly active antiretroviral therapy","volume":"119","author":"Lenner","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2018.04.031_bib6","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1378\/chest.124.3.929","article-title":"Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence","volume":"124","author":"Morris","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2018.04.031_bib7","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2007.078840","article-title":"Relapse of sarcoidosis upon treatment with etanercept","volume":"67","author":"Louie","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jtho.2018.04.031_bib8","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3899\/jrheum.090307","article-title":"Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge","volume":"36","author":"van der Stoep","year":"2009","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jtho.2018.04.031_bib9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1600-0560.2011.01795.x","article-title":"Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab","volume":"39","author":"Burns","year":"2012","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.jtho.2018.04.031_bib10","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s10067-007-0594-1","article-title":"Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients","volume":"26","author":"Verschueren","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"suppl 4","key":"10.1016\/j.jtho.2018.04.031_bib11","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.04.031_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jtho.2018.04.031_bib13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1146\/annurev-bioeng-101515-014413","article-title":"Implications of lymphatic transport to lymph nodes in immunity and immunotherapy","volume":"18","author":"Thomas","year":"2016","journal-title":"Annu Rev Biomed Eng"},{"key":"10.1016\/j.jtho.2018.04.031_bib14","doi-asserted-by":"crossref","first-page":"8890","DOI":"10.18632\/oncotarget.12985","article-title":"Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1\/PDL-1 treatment","volume":"8","author":"Botticelli","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2018.04.031_bib15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/annonc\/mdw534","article-title":"Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies","volume":"28","author":"Salama","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.04.031_bib16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2018.04.031_bib17","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1634\/theoncologist.2009-0028","article-title":"What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?","volume":"14","author":"Robert","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2018.04.031_bib18","first-page":"89","article-title":"Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma","volume":"35","author":"Weber","year":"2012","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.jtho.2018.04.031_bib19","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/cncr.24951","article-title":"Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2\u00a0doses correlates with survival","volume":"116","author":"Ku","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2018.04.031_bib20","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00262-011-1172-6","article-title":"An immune-active tumor microenvironment favors clinical response to ipilimumab","volume":"61","author":"Ji","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jtho.2018.04.031_bib21","first-page":"24","article-title":"Cells and cytokines involved in the pathogenesis of sarcoidosis","volume":"16","author":"Moller","year":"1999","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.jtho.2018.04.031_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1479-5876-7-35","article-title":"CTLA4 blockade increases Th17 cells in patients with metastatic melanoma","volume":"7","author":"von Euw","year":"2009","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.jtho.2018.04.031_bib23","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood-2007-11-120998","article-title":"Tumor-specific Th17-polarized cells eradicate large established melanoma","volume":"112","author":"Muranski","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtho.2018.04.031_bib24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/thx.2010.140319","article-title":"Sarcoidosis is a Th1\/Th17 multisystem disorder","volume":"66","author":"Facco","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.jtho.2018.04.031_bib25","doi-asserted-by":"crossref","first-page":"21463","DOI":"10.3390\/ijms141121463","article-title":"Imbalance between Th17 and regulatory T-Cells in sarcoidosis","volume":"14","author":"Huang","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtho.2018.04.031_bib26","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1164\/rccm.201503-0418OC","article-title":"Identification of immune-relevant factors conferring sarcoidosis genetic risk","volume":"192","author":"Fischer","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtho.2018.04.031_bib27","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2018.04.031_bib28","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1164\/rccm.201401-0188OC","article-title":"Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity","volume":"190","author":"Braun","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtho.2018.04.031_bib29","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1164\/rccm.201507-1499OC","article-title":"IFN-g\u2013producing T-helper 17.1 cells are increased in sarcoidosis and more prevalent than T-helper type 1 cells","volume":"193","author":"Ramstein","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtho.2018.04.031_bib30","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/1756-185X.13076","article-title":"Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis","volume":"20","author":"Lomax","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jtho.2018.04.031_bib31","first-page":"1355","article-title":"Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor","volume":"32","author":"Wilgenhof","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtho.2018.04.031_bib32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000161122","article-title":"Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient","volume":"218","author":"Eckert","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.jtho.2018.04.031_bib33","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","article-title":"Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab","volume":"3","author":"Tirumani","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtho.2018.04.031_bib34","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1200\/JCO.2011.39.3298","article-title":"Pulmonary sarcoid-like granulomatosis induced by ipilimumab","volume":"30","author":"Berthod","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.04.031_bib35","doi-asserted-by":"crossref","first-page":"W992","DOI":"10.2214\/AJR.10.6198","article-title":"Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy","volume":"197","author":"Bronstein","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jtho.2018.04.031_bib36","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/j.jaad.2013.07.028","article-title":"Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab","volume":"69","author":"Reule","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jtho.2018.04.031_bib37","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1183\/09031936.00107912","article-title":"Sarcoidosis complicating anti-cytotoxic T-lymphocyteassociated antigen-4 monoclonal antibody biotherapy","volume":"41","author":"Tissot","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2018.04.031_bib38","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/dth.12380","article-title":"Cutaneous sarcoidosis in a melanoma patient under Ipilimumab therapy","volume":"29","author":"Mart\u00ednez Lebor\u00e1ns","year":"2016","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jtho.2018.04.031_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-216217","article-title":"Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition","author":"Kim","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jtho.2018.04.031_bib40","doi-asserted-by":"crossref","first-page":"e954506","DOI":"10.4161\/21624011.2014.954506","article-title":"Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab","volume":"3","author":"Andersen","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2018.04.031_bib41","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10637-014-0092-7","article-title":"Kidney injuries related to ipilimumab","volume":"32","author":"Izzedine","year":"2014","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jtho.2018.04.031_bib42","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1097\/MJT.0b013e3182a32ddc","article-title":"Ipilimumab granulomatous interstitial nephritis","volume":"22","author":"Thajudeen","year":"2015","journal-title":"Am J Ther"},{"key":"10.1016\/j.jtho.2018.04.031_bib43","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1200\/JCO.2013.49.7735","article-title":"Antitumor granuloma formation by CD4 T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab","volume":"33","author":"Luke","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.04.031_bib44","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000362614","article-title":"New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment","volume":"37","author":"Murphy","year":"2014","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.jtho.2018.04.031_bib45","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40425-016-0199-9","article-title":"Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report and review of the literature","volume":"4","author":"Reuss","year":"2016","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2018.04.031_bib46","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.chest.2015.10.082","article-title":"Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma","volume":"149","author":"Danlos","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2018.04.031_bib47","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/bjd.14808","article-title":"Pulmonary sarcoid-like granulomatosis induced by nivolumab","volume":"176","author":"Montaudi\u00e9","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtho.2018.04.031_bib48","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jdcr.2016.06.004","article-title":"Pembrolizumab-associated sarcoidosis","volume":"2","author":"Cotliar","year":"2016","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jtho.2018.04.031_bib49","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/annonc\/mdw125","article-title":"Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab","volume":"27","author":"Cousin","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.04.031_bib50","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2018.04.031_bib51","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jdcr.2016.05.002","article-title":"Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy","volume":"2","author":"Suozzi","year":"2016","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jtho.2018.04.031_bib52","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/1078155216667635","article-title":"Sarcoidosis-like syndrome and lymphadenopathy due to\u00a0checkpoint inhibitors","volume":"23","author":"Firwana","year":"2017","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.jtho.2018.04.031_bib53","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1\/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis","volume":"82","author":"Le Burel","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2018.04.031_bib54","doi-asserted-by":"crossref","first-page":"W241","DOI":"10.2214\/AJR.10.6032","article-title":"Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab","volume":"197","author":"O\u2019Regan","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jtho.2018.04.031_bib55","first-page":"455","article-title":"Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma","volume":"29","author":"Maker","year":"2006","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.jtho.2018.04.031_bib56","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.04.031_bib57","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1200\/JCO.2011.37.9693","article-title":"Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission","volume":"30","author":"Vogel","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.04.031_bib58","doi-asserted-by":"crossref","first-page":"e1068","DOI":"10.1097\/MJT.0000000000000266","article-title":"Ipilimumab-induced granulomatous disease occurring simultaneously with disease progression in a patient with metastatic melanoma","volume":"23","author":"Toumeh","year":"2016","journal-title":"Am J Ther"},{"key":"10.1016\/j.jtho.2018.04.031_bib59","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(12)70007-4","article-title":"Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase\u00a01 dose-escalation trial","volume":"13","author":"van den Eertwegh","year":"2012","journal-title":"Lancet Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086418305938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086418305938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:38:10Z","timestamp":1761561490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086418305938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1556086418305938"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2018.04.031","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2018.04.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}